

Classification: Biological Sciences - Immunology and Inflammation

Fetal public V γ 9V δ 2 T cells expand and gain potent cytotoxic functions early after birth

Maria Papadopoulou^{1,2}, Tanya Dimova², Muki Shey³, Libby Briel³, Helen Veldtsman³, Nondumiso Khomba³, Hadn Africa³, Marcia Steyn³, Willem A. Hanekom³, Thomas J. Scriba³, Elisa Nemes³, David Vermijlen^{1,2*}

Affiliations:

1. Department of Pharmacotherapy and Pharmaceutics, Université Libre de Bruxelles (ULB), 1050 Brussels, Belgium
2. Institute for Medical Immunology (IMI), Université Libre de Bruxelles (ULB), 6041 Gosselies, Belgium
3. South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, Department of Pathology, Division of Immunology, University of Cape Town, 7925 Observatory, South Africa

Present address for T. Dimova: Institute of Biology and Immunology of Reproduction, Bulgarian Academy of Sciences, Bulgaria

*Corresponding author: David Vermijlen, dvermijl@ulb.ac.be

Keywords:

$\gamma\delta$ T cells, gammadelta, newborns, infant, human immunology, phosphoantigen, BCG, vaccination, TCR, CDR3 repertoire

Abstract

V γ 9V δ 2 T cells are a major human blood $\gamma\delta$ T cell population that respond in a T cell receptor (TCR)-dependent manner to phosphoantigens which are generated by a variety of microorganisms. It is not clear how V γ 9V δ 2 T cells react towards the sudden microbial exposure early after birth. We found that human V γ 9V δ 2 T cells with a public/shared fetal-derived TCR repertoire expanded within 10 weeks postpartum. Such an expansion was not observed in the nonV γ 9V δ 2 $\gamma\delta$ T cells, which possessed a private TCR repertoire. Furthermore, only the V γ 9V δ 2 T cells differentiated into potent cytotoxic effector cells by 10 weeks of age, despite their fetal origin. Both the expansion of public fetal V γ 9V δ 2 T cells and their functional differentiation were not affected by newborn vaccination with the phosphoantigen-containing BCG vaccine. These findings suggest a strong and early priming of the public fetal-derived V γ 9V δ 2 T cells promptly after birth, likely upon environmental phosphoantigen exposure.

Significance statement

Early life immune responses have been described as suboptimal with neonates and infants being susceptible to infections. V γ 9V δ 2 T cells are the first T lymphocytes to be generated in the human fetus. Their T cell receptor-mediated responses to in vitro stimulation and their effector functions at birth are weaker compared to those in adults, possibly reflecting the need for tolerance in utero. However, here we show that upon transition to the prominent microbial exposure early after birth, public fetal-derived V γ 9V δ 2 T cells expand and differentiate into potent cytotoxic effector cells. Thus, they provide newborns with a first line of anti-microbial effector T cells in order to combat infections in early life.

Introduction

Together with $\alpha\beta$ T cell and B cells, $\gamma\delta$ T cells have been conserved since the emergence of jawed vertebrates more than 450 million years ago and can play an important role in anti-microbial and anti-tumor immunity(1–3). $\gamma\delta$ T cells are the first T cells made during embryonic development in virtually all species examined and are thought to play an important role especially in conditions when $\alpha\beta$ T cell responses are impaired such as in early life(1, 4–10).

$\gamma\delta$ T cells, like $\alpha\beta$ T cells and B cells, use V(D)J gene rearrangement with the potential to generate a set of highly diverse receptors to recognize antigens. This diversity is generated mainly in the complementary-determining region 3 (CDR3) of the T cell receptor (TCR) via combinatorial and junctional diversity(11, 12). $V\gamma9V\delta2$ T cells express a TCR containing the γ -chain variable region 9 ($V\gamma9$, TRGV9) and the δ -chain variable region 2 ($V\delta2$, TRDV2) and are the dominant population of $\gamma\delta$ T cells in peripheral blood of human adults. They are activated and expanded in a TCR-dependent manner by microbe- and host-derived phosphorylated prenyl metabolites (phosphorylated antigens or ‘phosphoantigens’), derived from the isoprenoid metabolic pathway(13–15). This recognition of phosphoantigens allows $V\gamma9V\delta2$ T cells to develop potent antimicrobial and anticancer responses(3, 13, 16–19). While $V\gamma9V\delta2$ T cells are also abundant in the blood of mid-gestation fetuses, they represent only a small percentage of $\gamma\delta$ T cells at birth(20, 21). Fetal and adult blood $V\gamma9V\delta2$ T cells have a different developmental origin (as revealed by TCR sequencing), show different phosphoantigen activation thresholds and adult $V\gamma9V\delta2$ T cells possess cytotoxic effector functions that are absent from their fetal counterparts(5, 20, 22). It is not clear, however, how $V\gamma9V\delta2$ T cells respond to the sudden environmental change at the transition from the (almost) sterile in utero environment to the microbial phosphoantigen exposure at birth. Furthermore, it is not known whether $V\gamma9V\delta2$ T cells found in the blood circulation early after birth are still ‘fetal-like’, or whether a switch towards ‘adult-like’ $V\gamma9V\delta2$ T cells has already been initiated.

The tuberculosis (TB) vaccine Bacille Calmette-Guérin (BCG) contains phosphoantigens(23, 24) and is administered at birth in TB endemic settings. In adult non-human primate models ($V\gamma9V\delta2$ T cells do not exist in rodents(25)), it has been shown that $V\gamma9V\delta2$ T cells expand upon BCG vaccination, which correlated with protection against TB(26). Consistent with these observations, $\gamma\delta$ T cell responses in human BCG-vaccinated adults and infants have been

reported(27–31). BCG can therefore be regarded as a potent V γ 9V δ 2 T cell activator to study V γ 9V δ 2 T cell responses in vivo, including in early life.

Here we found that V γ 9V δ 2 T cells expanded early after birth (within 10 weeks) and possessed a public TCR repertoire which was related to their fetal origin. Furthermore, despite their fetal origin and in contrast to private $\gamma\delta$ T cell subsets and conventional $\alpha\beta$ T cells, V γ 9V δ 2 T cells showed a pronounced differentiation towards adult-like cytotoxic effector cells. Finally, this early and strong V γ 9V δ 2 T cell response was not altered by newborn BCG vaccination, suggesting an important role of environmental exposure in the expansion and functional differentiation of fetal-derived V γ 9V δ 2 T cells in early life.

Results

V γ 9V δ 2 T cells expand early after birth

First, we measured the abundance of V γ 9V δ 2 T cells and other $\gamma\delta$ subsets (nonV γ 9V δ 2) in peripheral blood of 10-week-old infants and compared it to cord and adult blood. The frequencies of V γ 9V δ 2 T cells were higher in 10-week-old infants and adults compared to cord (Fig. 1A), an observation that was specific for this $\gamma\delta$ subset (Fig. 1A, right panel). Expression of the proliferation marker Ki-67 was highest in the 10-week old group, compared to both cord and adult blood, highlighting an active phase of proliferation early after birth (Fig. 1B).

Only the 10-week-old V γ 9V δ 2 TCR repertoire is public and fetal-derived

Compared to adult V γ 9V δ 2 T cells, fetal and cord blood V γ 9V δ 2 T cells respond poorly to microbial-derived phosphoantigens(5, 20, 32, 33). We investigated whether the expanded V γ 9V δ 2 T cells in infants were derived from fetal V γ 9V δ 2 T cells, or whether an ‘adult-like’ V γ 9V δ 2 developmental program was initiated immediately after birth. To answer this question, we compared the TCR repertoire of V γ 9V δ 2 and nonV γ 9V δ 2 $\gamma\delta$ T cells sorted from 10-week-old infants to the repertoire of their fetal and adult counterparts. The fetal TCR repertoire was characterized in blood collected at <30 (fetal) or at >37 weeks (cord) of gestation(22). The 10-week-old V γ 9V δ 2 TRD repertoire was highly shared between individuals, as demonstrated by the geometric mean of overlap frequencies (F) and number of clonotypes shared within the group (Fig. 2A-B left panels), in contrast to the adult repertoire. The 10-week-old TRD repertoire was even more shared (public) than that of cord blood and reached a similar level of overlap as observed for fetal V γ 9V δ 2 T cells (Fig. 2A-B, left panels). A range of different clonotypes contributed to this high proportion of sharing among 10-week-old infants (Fig. 2B, left panel); the most public clonotypes at 10 weeks are shown in Table 1. Of relevance, the two most abundant clonotypes, CACDVLGDTDKLIF and CACDILGDTDKLIF, have been described to be highly prevalent in pre-thymic fetal liver(34). Importantly, the high proportion of sharing within the TRD repertoire was specific for the V γ 9V δ 2 T cell subset. Indeed, the TRD repertoire of 10-week-old nonV γ 9V δ 2 T cells was completely private (unique in each individual) like in adult nonV γ 9V δ 2 T cells, despite showing a significant level of sharing at the fetal stage (Fig. 2A-B, right panels; Fig. S1A-B).

An important feature in the detection of the developmental origin is the number of N additions used during the formation of the CDR3 by V(D)J recombination(22). The 10-week-old V γ 9V δ 2 CDR3 δ repertoire possessed a low fetal-like level of N additions (Fig. 2C, left

panel), which was again specific for the V γ 9V δ 2 T cells. NonV γ 9V δ 2 T cells from the same infants showed a high adult-like level of N additions in their CDR3 δ sequences (Fig. 2C, right panel). In line with an important contribution of fetal-derived V γ 9V δ 2 T cells to the 10-week V γ 9V δ 2 TCR repertoire, was the relative high usage of the fetal-like TRDJ2-3 segments at the expense of adult-like TRDJ1 (Fig. 2D, left panel). TRDJ2-3 are longer than TRDJ1 and therefore probably contribute to the maintenance of the CDR3 δ length at 10 weeks compared to adult V γ 9V δ 2 T cells (Fig. 2E, left panel), despite a lower number of N additions (Fig. 2C). TRDJ usage of the nonV γ 9V δ 2 T cells was similar in infants and adults, but different to fetal cells (Fig. 2D, right panel). Of note, the high proportion of 10-week-old V γ 9V δ 2 TRD repertoire sharing was not directly associated with the preferential usage of TRDJ3. Indeed, TRDJ1-containing CDR3 δ sequences of 10-week-old V γ 9V δ 2 T cells showed even a higher degree of overlap than TRDJ3-containing CDR3 δ sequences (Fig. 2F). To investigate the fetal origin of the 10-week-old V γ 9V δ 2 T cells more directly, we examined the level of sharing between the 10-week-old CDR3 δ repertoire and the other groups and observed that around 30% is similar to the fetal, while the overlap with the cord and adult repertoire was significantly lower (Fig. 2G, left panel, Fig. 2H). Once more, this was highly specific for the V γ 9V δ 2 subset, as such sharing was not observed between 10-week-old and fetal nonV γ 9V δ 2 T cells (Fig. 2G, right panel, Fig. S1C-D). The high sharing between fetal and 10-week-old V γ 9V δ 2 T cells was due to a relatively high number of clonotypes and not just a few abundant fetal ones (Fig. 2H-I). The lower overlap found in cord (Fig. 2A) was in line with a higher diversity estimation (D25; percentage of unique clonotypes required to account for 25% of total repertoire) which was reduced at 10-weeks with the expansion of (fetal-derived) V γ 9V δ 2 T cells (Fig. S1E). Results of analyzing the CDR3 γ repertoire (Fig. S2) were similar to those of the CDR3 δ repertoire (Fig. 2), with the main exception that the adult TRGV9 was largely public (Fig. S2), in line with previous studies(22, 35, 36).

In summary, TCR sequencing indicates that a large fraction of the early post-natal expanded infant V γ 9V δ 2 T cells are derived from <30-week gestation fetal public V γ 9V δ 2 T cells.

Fetal-derived V γ 9V δ 2 T cells get activated and become highly cytotoxic rapidly after birth

Next, we investigated whether fetal-derived V γ 9V δ 2 T cells expanded early after birth were functionally mature. 10-week-old V γ 9V δ 2 T cells were highly activated compared to cord V γ 9V δ 2 T cells, and, more surprisingly, also compared to adult V γ 9V δ 2 T cells (Fig. 3A, Fig. S3A). In addition, at 10 weeks they started to gradually differentiate by losing the expression

of CD27 and CD28 (Fig. 3B). However, this did not lead to a significant increase in fully differentiated cells, as observed for adult V γ 9V δ 2 T cells (Fig. 3B right panel, Fig. S3B).

Aside from their TCR, V γ 9V δ 2 T cells can also use NK receptors (NKR) to recognize target cells(37). We verified the expression of a series of NKR and found that 10-week old V γ 9V δ 2 T cells specifically showed increased expression of the inhibitory NKR NKG2A compared to cord blood, while other T cell subsets and other NKR (CD161, KLRG1, CD158a/b, NKG2C) did not show such expression pattern (Fig. 3C-D; Fig. S3C). NKG2D, an important activating NKR for $\gamma\delta$ T cells, including the V γ 9V δ 2 subset(37), was already highly expressed by cord blood V γ 9V δ 2 T cells and was not further increased after birth (Fig. 3D).

A major function of V γ 9V δ 2 T cells in adults is killing of infected and cancer cells(3, 16, 18). We evaluated the cytotoxic potential of the V γ 9V δ 2 T cells in detail by analyzing different cytotoxic mediators that each play a different role in the killing machinery(38). At birth, V γ 9V δ 2 T cells lacked the expression of granzyme B and perforin, a combination that is known to efficiently kill infected cells via apoptosis(38). Strikingly, at 10-weeks, despite their relatively limited differentiation (Fig. S3B), the V γ 9V δ 2 T cells co-expressed these cytotoxic mediators at adult-like levels (Fig. 3E-G). Interestingly, while all the T cell subsets in adults expressed granzyme B and perforin, in early life expression of these markers was restricted to the V γ 9V δ 2 T cell subset (Fig. 3E-F). Granulysin can mediate specific killing of intracellular and extracellular microbes(39, 40). In contrast to perforin and granzyme B, granulysin was almost absent in early life and reached only high levels of expression in adults (Fig. 3G-H). Granzyme A mediates killing of target cells by a different mechanism than granzyme B, and is known to have alternative roles to cytotoxic activity(38, 41, 42). Granzyme A was already expressed in cord specifically by V γ 9V δ 2 T cells (Fig. 3I), as observed previously in fetal (<30 weeks gestation) V γ 9V δ 2 T cells(20). This expression further increased in 10-week V γ 9V δ 2 T cells and remained highly restricted to the V γ 9V δ 2 T cell subset (Fig. 3I). In addition, the per-cell expression was even higher in infant compared to adult V γ 9V δ 2 T cells (Fig. 3G, Fig. S3D).

In summary, 10-week-old V γ 9V δ 2 T cells are highly activated and express a particular pattern of cytotoxic mediators that is clearly different from V γ 9V δ 2 T cells at birth (high perforin and granzyme B), as well as from adult V γ 9V δ 2 T cells (absence of granulysin, higher granzyme A).

Cytokine expression capacity by V γ 9V δ 2 T cells is mainly determined before birth

As $\gamma\delta$ T cells can be rapidly activated to produce effector cytokines such as IFN γ and TNF α (1–3), we explored this effector capacity with strong short-term stimulation by PMA and ionomycin. We observed high expression of the two cytokines by cord, 10-week-old and adult

V γ 9V δ 2 T cells (Fig. 4A-B). V γ 9V δ 2 T cells were the main producers of IFN γ in early life, while in adults other T cells expressed IFN γ as well (Fig. 4A). While the percentage of V γ 9V δ 2 expressing IFN γ and TNF α remained stable at 10 weeks (compared to cord blood), 10-week-old V γ 9V δ 2 T cells expressed much more IFN γ (but not TNF α) per cell (Fig. 4A, right panel, Fig 4B right panel, Fig. S3E). The high percentage of V γ 9V δ 2 T cells expressing IFN γ within cord and infant V γ 9V δ 2 T cells was paralleled by expression of the transcription factors T-bet and Eomes (Fig. 4C), which are known to be important for IFN γ production in $\gamma\delta$ T cells(43). Thus, the cytokine expression capacity (IFN γ , TNF α and associated transcription factors) of V γ 9V δ 2 T cells is mainly programmed before birth while the IFN γ levels per V γ 9V δ 2 T cell is highly increased early after birth.

Phosphoantigen-reactivity remains stable early after birth

It is known that fetal and cord blood-derived V γ 9V δ 2 T cells show a significantly reduced response towards phosphoantigens such as the microbial-derived (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP)(13, 20, 32, 33), compared to adult-derived V γ 9V δ 2 T cells. However, it is not clear whether this response would change early after birth(5). HMBPP induced comparable low levels of IFN γ in infant V γ 9V δ 2 T cells as observed in cord blood (Fig. 4D), while the higher response of adult V γ 9V δ 2 was confirmed (Fig. 4D). Further, treatment with zoledronic acid, which leads to intracellular isopentenyl pyrophosphate (IPP) accumulation and depends on different accessory leukocyte populations than HMBPP(33, 44), also did not lead to a higher IFN γ production in 10-week-old V γ 9V δ 2 T cells compared to cord (Fig. 4E). Thus, upon functional differentiation early after birth, the fetal-derived V γ 9V δ 2 T cells do not show an increase of their phosphoantigen-reactivity towards adult-like levels.

BCG vaccination at birth does not alter the TCR repertoire nor functional differentiation of V γ 9V δ 2 T cells

Next, we investigated whether the expansion and associated activation and functional maturation of 10-week-old V γ 9V δ 2 T cells could be influenced by vaccination at birth with BCG, a known V γ 9V δ 2 T cell activator(23, 24, 26, 45) which can also expand cord blood V γ 9V δ 2 T cells in vitro(32). Thus, we compared the function and repertoire of V γ 9V δ 2 T cells from 10-week-old infants who received BCG vaccination at birth (BCG+) with infants who did not receive vaccination at birth (BCG-).

To our surprise, frequencies of V γ 9V δ 2 T cells were not increased in BCG+ compared to BCG- infants (Fig. 5A, top panel). This was confirmed by a very similar proliferation rate ex-vivo (Fig.

5A, bottom panel). We further investigated the shaping of the repertoire in detail early after birth (Fig. 1B-H), which may shed light on how the TCR repertoire changed in response to a specific stimulus (BCG)(17). Overall, TCR diversity (Fig. 5B-C), number of N additions (Fig. 5D), usage of J segment (Fig. 5E), CDR3 length (Fig. 5F), and level of repertoire overlap (Fig. 5G-H) were not significantly different between BCG- and BCG+ infants.

A detailed analysis of the phenotype and effector functions of infant V γ 9V δ 2 T cells indicated that BCG vaccination did not influence the rapid and striking differentiation of the neonatal V γ 9V δ 2 T cells early after birth (Fig. 6, Fig. S4).

Overall, these data suggest that the expansion of public fetal-derived V γ 9V δ 2 T cells and their functional differentiation early after birth, most likely upon environmental (phosphoantigen) exposure, are not altered by the administration of the phosphoantigen-containing vaccine BCG at birth.

Discussion

Compared to adult blood V γ 9V δ 2 T cells, cord blood V γ 9V δ 2 T cells show only a limited expansion upon in vitro phosphoantigen stimulation(5, 20, 32, 33). Despite this, we show here that within ten weeks of birth V γ 9V δ 2 T cells from healthy infants were already expanding. Furthermore, TCR repertoire analysis indicated a preferential expansion of early fetal-derived (<30 weeks of gestation) clonotypes, showing a high level of sharing. Consistent with this was the identification of CACDVLGDTDKLIF and CACDILGDTDKLIF among the top shared TRD sequences in 10-week-old V γ 9V δ 2 T cells, previously described to be highly abundant and shared in pre-thymic livers of 6/7-week gestation fetuses(34). Hence, it appears that public V γ 9V δ 2 clonotypes, derived from fetal thymus(22) and/or fetal liver(34), are maintained until birth and show a preferential expansion upon birth. In sharp contrast, the other blood $\gamma\delta$ T cell subsets (grouped as nonV γ 9V δ 2 T cells, not responding to phosphoantigens), which also showed TCR repertoire overlap at the fetal stage, became private at term delivery and did not expand early after birth. In adults, the TRD repertoire of both V γ 9V δ 2 and nonV γ 9V δ 2 T cells were private, consistent with other studies(35, 36, 46). A major potential source of phosphoantigens in the first weeks after birth is the developing microbiota(47). Indeed, HMBPP, the most potent natural phosphoantigen, is produced by multiple bacterial species that are present in the gut microbiome and can induce a polyclonal expansion of fetal/cord V γ 9V δ 2 T cells in vitro(13, 22, 47–49). The high phosphoantigen-activation threshold early after birth may be reduced by factors such as innate cytokines (IL-18, IL-23) that are then highly expressed(50). Indeed, fetal/cord blood V γ 9V δ 2 T cells show an increased in vitro phosphoantigen responsiveness when co-incubated with IL-18 or IL-23, they show high expression of the IL-18 receptor and the expression of the IL-23 receptor is induced upon phosphoantigen exposure(20, 33, 44). A previous study has shown increasing percentages of total V δ 2+ T cells (thus not making the distinction between V γ 9+V δ 2+ and V γ 9-V δ 2+ T cells) in children between 3-10 years, possibly reflecting expansion of 'adult-like' V γ 9V δ 2 T cells(21). Compared to samples collected >1 year after birth, the number of samples collected <1 year were more limited in this study, possibly explaining the lack of observing a clear increase in V δ 2+ percentages early after birth. In addition, the decrease of V γ 9-V δ 2+ cells after birth(6, 36, 51) could have masked a clear increase of V γ 9+V δ 2+ cells when gating on total V δ 2+ T cells at this age.

A recent study investigated the association of 62 leukocyte subsets from birth until 6 years with a series of nongenetic determinants (prenatal maternal lifestyle-related or immune-mediated determinants, birth characteristics and bacterial/viral exposure-related determinants)(52). Interestingly, among the 26 different determinants investigated, only 'premature rupture of membranes' was found to be associated with V γ 9V δ 2 T cell levels(52). At premature gestation times V γ 9V δ 2 T cells are the main subset, while at term-delivery V δ 1+ γ δ T cells are predominant(20, 53). Since we show here that fetal-derived V γ 9V δ 2 T cells expand immediately upon delivery, the higher initial V γ 9V δ 2 T cell levels upon premature birth can explain the association of V γ 9V δ 2 T cells in infants and young children that were born prematurely.

In contrast to the private γ δ T cell subsets (nonV γ 9V δ 2), at 10 weeks after birth the public V γ 9V δ 2 T cells were activated and differentiated towards high expression of cytotoxic mediators (perforin, granzyme B, granzyme A). While variable perforin expression has been described in pediatric V δ 2+ cells(5) (containing both the V γ 9+V δ 2+ and V γ 9-V δ 2+ subset(5, 20, 36, 51)), we define here that its expression is limited to the V γ 9+V δ 2+ subset early after birth. Granzyme B, together with perforin, can efficiently kill infected target cells(38). Therefore, their co-expression in 10-week-old V γ 9V δ 2 T cells suggests that these cells are potent cytotoxic effectors against (phosphoantigen-generating) infections early after birth. Granzyme A, which is highly expressed by 10-week-old V γ 9V δ 2 T cells, at levels even higher than in adults, can induce a different cell death pathway than granzyme B(38). Furthermore, granzyme A produced by V γ 9V δ 2 T cells promotes inhibition of mycobacterial growth in macrophages(42). Thus, the very high granzyme A expression observed in 10-week-old V γ 9V δ 2 T cells can play an important role in the killing of infected cells and/or the inhibition of intracellular growth of pathogens. Unlike perforin and granzyme B expression, the cytokine expression capacity (IFN γ , TNF α and associated transcription factors) of V γ 9V δ 2 T cells was mainly programmed before birth. Among NKR, NKG2A was highly upregulated early after birth on the cell surface V γ 9V δ 2 T cells, which can be triggered by phosphoantigen exposure(54). The similar expression patterns of the cytotoxic mediators perforin/granzyme B and the inhibitory NKR NKG2A in 10-week old V γ 9V δ 2 T cells suggest that NKG2A signaling could regulate potent cytotoxic activity of infant V γ 9V δ 2 T cells. Granulysin is a cytotoxic mediator that, like V γ 9V δ 2 T cells, is not present in rodents. It can target pathogens directly rather than the infected cells(40). As opposed to cord-and 10-week V γ 9V γ 2 T cells, granulysin was highly expressed by adult V γ 9V δ 2 T cells. Furthermore, adult V γ 9V δ 2 T cells clearly showed a higher

response towards HMBPP compared to 10-week and cord blood V γ 9V δ 2 T cells. These specific features of V γ 9V δ 2 T cells in adult blood circulation may be due to their distinct development compared to fetal-derived V γ 9V δ 2 T cells(22).

No influence of vaccination with BCG (a known V γ 9V δ 2 T cell activator) at birth could be observed in 10-week-old V γ 9V δ 2 T cells, with regards to their expansion, TCR repertoire and function. It has been previously suggested that V γ 9V δ 2 T cells can be activated by BCG vaccination in early life (29–31), but these studies did not consider age-matched unvaccinated controls. A possible explanation for the absence of BCG-induced effects on infant V γ 9V δ 2 T cells is that the expansion due to the sudden microbial phosphoantigen exposure at birth (including the developing microbiome) overrides a possible effect of BCG administration detectable by 10 weeks of age. This could explain why clear expansions of V γ 9V δ 2 T cells can be seen in non-human primates (NHP) (in clean facilities) upon vaccination with BCG(26). Moreover, intravenous administration (instead of the routine intradermal administration practiced in humans) and the higher dosage of BCG vaccine used in NHP studies (26, 55) seem to favor the activation of immune cells as demonstrated recently by Darrah and colleagues(56). In this study, there was an increase of peripheral V γ 9+ γ δ T cells only after high-dose intravenous BCG administration (and not intradermal), which was notably transient(56). In addition, the distinct development of fetal and adult V γ 9V δ 2 T cells may contribute to different responses to vaccination with BCG, depending on the age of the vaccinated donors(22, 27, 28). Of note, γ δ T cells have been increasingly recognized as important players in vaccine-mediated protection from infection(57). As our study shows that fetal-derived V γ 9V δ 2 T cells are expanded and functionally differentiated early after birth independently from BCG vaccination, it highlights the need for correct (age-matched) control groups when investigating γ δ T cells in vaccination studies. While vaccination with BCG has been shown to lead to heterologous or non-specific effects, including via the induction of trained immunity in innate immune cells such as monocytes (also known as innate memory)(58, 59), our study indicates that innate V γ 9V δ 2 T cells are rather ‘trained’ by the overt phosphoantigen exposure they encounter after birth.

Collectively, our study shows that in the first two months after birth, fetal-derived V γ 9V δ 2 T cells expressing public/shared TCRs specifically expand and differentiate to a cytotoxic subset with functions closer to those seen in adults than the fetal counterparts. This differentiation is not affected by BCG vaccination at birth, a strong γ δ stimulus, which is likely due to

prominent environmental exposure. This post-natal polyclonal burst of $V\gamma 9V\delta 2$ T cells combined with strong functional maturation shapes an innate T cell subset in newborns that may be important to fight infections at a time when the conventional (memory) $\alpha\beta$ T cell response is not fully active(60).

Materials and Methods

Study Populations

We compared host responses of 10-week-old infants (10w) with those in cord and adult blood. The 10-week-old infants consisted of two groups, one vaccinated with BCG intradermally (Danish 1331 strain, Statens Serum Institut, Denmark) at birth as is routine in South Africa (BCG+, median age 65 days, min 56 – max 77), and another group not vaccinated with BCG at birth (BCG-, median age 67.5 days, min 61 – max 86). In those not vaccinated at birth, BCG vaccine was administered at 10 weeks of age, immediately after blood collection. Control samples were collected from newborns (cord blood) and adults from the same community (all independent donors).

Newborns, infants and adults were enrolled at the South African Tuberculosis Vaccine Initiative (SATVI) field site, near Cape Town, and at private and public clinics in Worcester, South Africa. The protocol was approved by the University of Cape Town Human Research Ethics Committee (ref 177/2011). Written, informed consent was obtained from legal guardians of all infants and from adult donors.

Exclusion criteria for mothers included delivery through Caesarean section (except for cord blood, which was collected from women undergoing elective Caesarean section), significant complications during pregnancy, possible relocation to a different region, HIV+ or unknown/undisclosed HIV status, known chronic infections or any acute infection during the last trimester of pregnancy, suspicion of TB or known household contact with TB patients.

Exclusion criteria for infants included BCG vaccination before planned blood collection at 10 weeks of age (for the delayed group) or BCG vaccination not received at birth (for the group receiving routine BCG), current suspicion of TB or known household contact with TB patients in the first 10 weeks of life, isoniazid (INH) therapy during the first 10 weeks of life, any chronic disease in the first 10 weeks of life, any acute disease during the 2 weeks before blood collection, infants born before 37 weeks of gestation (preterm) and those with low birth weight (<2500g), congenital malformations or perinatal complications such as birth asphyxia, respiratory distress and severe jaundice, or chronic or current use of immunosuppressant treatments such as steroids.

Exclusion criteria for adults included chronic use of immune-modifying drugs in the last 6 months, any acute or chronic illness, history of TB disease, pregnant or lactating females.

Whole blood was collected in CPT tubes or heparinized polypropylene tubes. Peripheral blood mononuclear cells (PBMC) were isolated from blood, cryopreserved, and shipped to Belgium for further analysis.

For the CDR3 repertoire analysis, 10-week-old V γ 9V δ 2 T cells were compared to fetal blood. Since the fetal blood samples originated from Belgium (no access to South-African fetal blood during this study), cord and adult blood from Belgium were included in parallel to the South-African cohort (cord, 10-week-old, adult blood). The Belgian samples (fetal, cord and adult blood) analyzed here were previously described(22). Briefly, samples included fetal blood because of interruption of pregnancy (22-30 weeks of gestation), approved by the Hôpital Erasme ethics committee; umbilical cord blood after delivery (vaginal) (39-41 weeks term delivery) with the approval of the University Hospital Center Saint-Pierre; adult peripheral blood, approved by the Ethics committee of the CHU Tivoli, La Louvière. PBMC were isolated from blood and cryopreserved for subsequent experiments.

Methods

Flow cytometry, sorting and cell cultures, TCR γ (TRG) and TCR δ (TRD) high-throughput sequencing and statistical analysis are described in SI Appendix, Supplemental Methods.

Data availability

Fastq files of TRG and TRD sequences are deposited under SRA accession code PRJNA624366.

Acknowledgements

We are grateful to the mothers and infants that participated to this study. We are also grateful for the key contribution of Ms Bernadette Pienaar, Study Coordinator at SATVI, who has prematurely passed. We thank the GIGA Genomics platform (Latifa Karim and Wouter Coppieters) for their outstanding technical support. This work was supported by the FNRS (J.0078.13), the European Regional Development Fund (FEDER Immunomarquers) and an ARC (Action de Recherche Concertée) grant of the ULB. MP is supported by the FNRS (FRIA), Fonds Van Buuren-Jaumotte-Demoulin and Fonds Hoguet. This article is published with the support of the Fondation Universitaire of Belgium.

Author contributions

MP and TD designed and undertook experiments; MSh, LB, HV, NK, HA, MSt, WAH, TJS and EN were involved in clinical design and execution, including blood collection and storage; MP, TD and DV processed and interpreted data; TD, TJS and EN revised the manuscript; MP and DV wrote the manuscript and DV designed the study.

Competing interests

The authors declare no competing interests.

References

1. A. C. Hayday, $\gamma\delta$ Cells: A Right Time and a Right Place for a Conserved Third Way of Protection. *Annu. Rev. Immunol.* **18**, 975–1026 (2000).
2. Y. Chien, C. Meyer, M. Bonneville, $\gamma\delta$ T Cells: First Line of Defense and Beyond. *Annu. Rev. Immunol.* **32**, 121–155 (2014).
3. B. Silva-Santos, K. Serre, H. Norell, $\gamma\delta$ T cells in cancer. *Nat. Rev. Immunol.* **15**, 683–691 (2015).
4. E. Ramsburg, R. Tigelaar, J. Craft, A. Hayday, Age-dependent Requirement for $\gamma\delta$ T Cells in the Primary but Not Secondary Protective Immune Response against an Intestinal Parasite. *J. Exp. Med.* **198**, 1403–1414 (2003).
5. S. C. De Rosa, *et al.*, Ontogeny of $\gamma\delta$ T Cells in Humans. *J. Immunol.* **172**, 1637–1645 (2004).
6. D. Vermijlen, *et al.*, Human cytomegalovirus elicits fetal $\gamma\delta$ T cell responses in utero. *J. Exp. Med.* **207**, 807–821 (2010).
7. D. Vermijlen, I. Prinz, Ontogeny of innate T lymphocytes - some innate lymphocytes are more innate than others. *Front. Immunol.* **5**, 1–12 (2014).
8. A. C. Hayday, $\gamma\delta$ T Cell Update: Adaptate Orchestrators of Immune Surveillance. *J. Immunol.* **203**, 311–320 (2019).
9. P. Jagannathan, *et al.*, V δ 2+ T cell response to malaria correlates with protection from infection but is attenuated with repeated exposure. *Sci. Rep.* **7**, 1–12 (2017).
10. P. Tieppo, *et al.*, The human fetal thymus generates invariant effector $\gamma\delta$ T cells. *J. Exp. Med.* **217**, e20190580 (2020).
11. Y. H. Chien, Y. Konigshofer, Antigen recognition by $\gamma\delta$ T cells. *Immunol. Rev.* **215**, 46–58 (2007).
12. L. D. Notarangelo, M. S. Kim, J. E. Walter, Y. N. Lee, Human RAG mutations: Biochemistry and clinical implications. *Nat. Rev. Immunol.* **16**, 234–246 (2016).
13. M. Eberl, *et al.*, Microbial isoprenoid biosynthesis and human $\gamma\delta$ T cell activation. *FEBS Lett.* **544**, 4–10 (2003).
14. L. Boutin, E. Scotet, Towards deciphering the hidden mechanisms that contribute to the antigenic activation process of human V γ 9V δ 2 T cells. *Front. Immunol.* **9** (2018).
15. D. Vermijlen, D. Gatti, A. Kouzeli, T. Rus, M. Eberl, $\gamma\delta$ T cell responses: How many ligands will it take till we know? *Semin. Cell Dev. Biol.* **84**, 75–86 (2018).
16. W. H. Boom, $\gamma\delta$ T cells and mycobacterium tuberculosis. *Microbes Infect.* **1**, 187–195 (1999).
17. C. T. Spencer, G. Abate, A. Blazevic, D. F. Hoft, Only a Subset of Phosphoantigen-Responsive $\gamma\delta$ 2 T Cells Mediate Protective Tuberculosis Immunity. *J. Immunol.* **181**, 4471–4484 (2008).
18. W. Tu, *et al.*, The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a $\gamma\delta$ T cell population in humanized mice. *J. Exp. Med.* **208**, 1511–1522 (2011).
19. L. Wang, A. Kamath, H. Das, L. Li, J. F. Bukowski, Antibacterial effect of human V γ 2V δ 2 T cells in vivo. *J. Clin. Invest.* **108**, 1349–1357 (2001).
20. T. Dimova, *et al.*, Effector v γ 9v δ 2 t cells dominate the human fetal $\gamma\delta$ t-cell repertoire. *Proc. Natl. Acad. Sci. U. S. A.* **112**, E556–E565 (2015).
21. C. M. Parker, *et al.*, Evidence for extrathymic changes in the T cell receptor γ/δ repertoire. *J. Exp. Med.* **171**, 1597–1612 (1990).
22. M. Papadopoulou, *et al.*, TCR Sequencing Reveals the Distinct Development of Fetal and Adult Human V γ 9V δ 2 T Cells. *J. Immunol.* **203**, 1468–1479 (2019).
23. M. Hintz, *et al.*, Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human $\gamma\delta$ T cells in Escherichia coli. *FEBS Lett.* **509**, 317–322 (2001).
24. Y. Zhang, *et al.*, Structural Studies of V γ 2V δ 2 T Cell Phosphoantigens. *Chem. Biol.* **13**, 985–992 (2006).
25. M. M. Karunakaran, T. W. Göbel, L. Starick, L. Walter, T. Herrmann, V γ 9 and V δ 2 T cell antigen receptor genes and butyrophilin 3 (BTN3) emerged with placental mammals and are concomitantly preserved in selected species like alpaca (*Vicugna pacos*). *Immunogenetics* **66**, 243–254 (2014).
26. Y. Shen, *et al.*, Adaptive immune response of V γ 2V δ 2+ T cells during mycobacterial infections. *Science (80-.)*. **295**, 2255–2258 (2002).
27. D. F. Hoft, R. M. Brown, S. T. Roodman, Bacille Calmette-Guérin vaccination enhances human gamma delta T cell responsiveness to mycobacteria suggestive of a memory-like phenotype. *J. Immunol.* **161**, 1045–54 (1998).

28. S. Suliman, *et al.*, Bacillus Calmette–Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses . *J. Immunol.* **197**, 1100–1110 (2016).
29. C. Zufferey, S. Germano, B. Dutta, N. Ritz, N. Curtis, The Contribution of Non-Conventional T Cells and NK Cells in the Mycobacterial-Specific IFN γ Response in Bacille Calmette–Guérin (BCG)-Immunized Infants. *PLoS One* **8**, 1–9 (2013).
30. T. N. Mazzola, *et al.*, Robust $\gamma\delta$ + T cell expansion in infants immunized at birth with BCG vaccine. *Vaccine* **25**, 6313–6320 (2007).
31. Y. Taştan, *et al.*, Influence of Bacillus Calmette–Guèrin vaccination at birth and 2 months old age on the peripheral blood T-cell subpopulations [γ / δ ($\gamma\delta$) and alpha-beta ($\alpha\beta$) T cell]. *Pediatr. Allergy Immunol.* **16**, 624–629 (2005).
32. C. Cairo, *et al.*, V δ 2 T-lymphocyte responses in cord blood samples from Italy and Côte d’Ivoire. *Immunology* **124**, 380–387 (2008).
33. E. Moens, *et al.*, IL-23R and TCR signaling drives the generation of neonatal V 9V 2 T cells expressing high levels of cytotoxic mediators and producing IFN- and IL-17. *J. Leukoc. Biol.* **89**, 743–752 (2011).
34. E. Origin, C. D. Fetal, Extrathymic Origin. *J. Immunol.* (1996).
35. S. Ravens, *et al.*, Human $\gamma\delta$ T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection. *Nat. Immunol.* **18**, 393–401 (2017).
36. M. S. Davey, *et al.*, The human V δ 2+ T-cell compartment comprises distinct innate-like V γ 9+ and adaptive V γ 9- subsets. *Nat. Commun.* **9** (2018).
37. B. Silva-Santos, J. Strid, Working in “NK mode”: Natural killer group 2 member D and natural cytotoxicity receptors in stress-surveillance by $\gamma\delta$ T cells. *Front. Immunol.* **9** (2018).
38. D. Chowdhury, J. Lieberman, Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death. *Annu. Rev. Immunol.* **26**, 389–420 (2008).
39. F. Dieli, *et al.*, Granulysin-Dependent Killing of Intracellular and Extracellular Mycobacterium tuberculosis by V γ 9/V δ 2 T Lymphocytes . *J. Infect. Dis.* **184**, 1082–1085 (2001).
40. F. Dotiwala, J. Lieberman, Granulysin: killer lymphocyte safeguard against microbes. *Curr. Opin. Immunol.* **60**, 19–29 (2019).
41. S. S. Metkar, *et al.*, Human and Mouse Granzyme A Induce a Proinflammatory Cytokine Response. *Immunity* **29**, 720–733 (2008).
42. C. T. Spencer, *et al.*, Granzyme A Produced by $\gamma\delta$ 2 T Cells Induces Human Macrophages to Inhibit Growth of an Intracellular Pathogen. *PLoS Pathog.* **9** (2013).
43. L. Chen, *et al.*, Epigenetic and Transcriptional Programs Lead to Default IFN- γ Production by $\gamma\delta$ T Cells. *J. Immunol.* **178**, 2730–2736 (2007).
44. P. T. Nerdal, *et al.*, Butyrophilin 3A/CD277–Dependent Activation of Human $\gamma\delta$ T Cells: Accessory Cell Capacity of Distinct Leukocyte Populations. *J. Immunol.* **197**, 3059–3068 (2016).
45. P. Constant, *et al.*, The antituberculous Mycobacterium bovis BCG vaccine is an attenuated mycobacterial producer of phosphorylated nonpeptidic antigens for human $\gamma\delta$ T cells. *Infect. Immun.* **63**, 4628–4633 (1995).
46. M. S. Davey, *et al.*, Clonal selection in the human V δ 1 T cell repertoire indicates $\gamma\delta$ TCR-dependent adaptive immune surveillance. *Nat. Commun.* **8**, 1–15 (2017).
47. R. C. Robertson, A. R. Manges, B. B. Finlay, A. J. Prendergast, The Human Microbiome and Child Growth – First 1000 Days and Beyond. *Trends Microbiol.* **27**, 131–147 (2019).
48. S. Tamburini, N. Shen, H. C. Wu, J. C. Clemente, The microbiome in early life: Implications for health outcomes. *Nat. Med.* **22**, 713–722 (2016).
49. A. S. Fichtner, S. Ravens, I. Prinz, Human $\gamma\delta$ TCR Repertoires in Health and Disease. *Cells* **9**, 800 (2020).
50. A. Olin, *et al.*, Stereotypic Immune System Development in Newborn Children. *Cell* **174**, 1277–1292.e14 (2018).
51. C. T. Morita, C. M. Parker, M. B. Brenner, H. Band, TCR usage and functional capabilities of human gamma delta T cells at birth. *J. Immunol.* **153**, 3979–88 (1994).
52. D. van den Heuvel, *et al.*, Effects of nongenetic factors on immune cell dynamics in early childhood: The Generation R Study. *J. Allergy Clin. Immunol.* **139**, 1923–1934.e17 (2017).
53. M. van der Heiden, *et al.*, Characterization of the $\gamma\delta$ T-cell compartment during infancy reveals clear differences between the early neonatal period and 2 years of age. *Immunol. Cell*

- Biol.* **98**, 79–87 (2020).
54. S. Boullier, *et al.*, Phosphoantigen activation induces surface translocation of intracellular CD94/NKG2A class I receptor on CD94- peripheral V γ 9 V δ 2 T cells but not on CD94- thymic or mature $\gamma\delta$ T cell clones. *Eur. J. Immunol.* **28**, 3399–3410 (1998).
 55. D. Zhou, *et al.*, Mycobacterium bovis bacille Calmette-Guérin enhances pathogenicity of simian immunodeficiency virus infection and accelerates progression to AIDS in macaques: a role of persistent T cell activation in AIDS pathogenesis. *J. Immunol.* **162**, 2204–16 (1999).
 56. P. A. Darrah, *et al.*, Prevention of tuberculosis in macaques after intravenous BCG immunization. *Nature* **577**, 95–102 (2020).
 57. K. W. Dantzler, L. de la Parte, P. Jagannathan, Emerging role of $\gamma\delta$ T cells in vaccine-mediated protection from infectious diseases. *Clin. Transl. Immunol.* **8** (2019).
 58. J. Kleinnijenhuis, *et al.*, Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. *Proc. Natl. Acad. Sci. U. S. A.* **109**, 17537–17542 (2012).
 59. L. C. J. de Bree, *et al.*, Non-specific effects of vaccines: Current evidence and potential implications. *Semin. Immunol.* **39**, 35–43 (2018).
 60. T. R. Kollmann, B. Kampmann, S. K. Mazmanian, A. Marchant, O. Levy, Protecting the Newborn and Young Infant from Infectious Diseases: Lessons from Immune Ontogeny. *Immunity* **46**, 350–363 (2017).

Figure legends:

Figure 1

V γ 9V δ 2 T cells expand early after birth.

- A. Frequencies of the V γ 9+V δ 2+ subset in CD3+ cells (left panel, bars indicate medians) and cumulative frequencies of V γ 9+V δ 2+ $\gamma\delta$ T cells, V γ 9+V δ 2- $\gamma\delta$ T cells, V γ 9-V δ 2+ $\gamma\delta$ T cells and V γ 9-V δ 2- $\gamma\delta$ T cells among CD3+ cells (right panel, error bars indicate means \pm SEM; $p > 0.5$ for the nonV γ 9V δ 2 $\gamma\delta$ T cell subsets between 10w and cord) in cord (n=18), 10-week-old (10w, n=36) and adult (n=17). Representative flow cytometry plots (bottom panel) gated on $\gamma\delta$ +CD3+ cells, percentages out of CD3+.
- B. Percentage of Ki-67+ cells among V γ 9V δ 2 T cells (cord, adult n=7, 10w n=14). Bars indicate medians. Representative flow cytometry plots (right panel).

Data shown from independent donors (South-African). P values are reported on graphs.

Figure 2

Only the 10-week-old V γ 9V δ 2 TCR repertoire is public and fetal-derived.

A-E. Description of the CDR3 TRD repertoire of sorted V γ 9V δ 2 T cells (left panels) and nonV γ 9V δ 2 $\gamma\delta$ T cells (right panels), derived from fetal (n=5, Belgian), cord (n=9, Belgian=6, South-African=3), 10w (n=14, South-African) and adult (n=11 for V γ 9V δ 2, Belgian=8, South-African=3 and n=8 for nonV γ 9V δ 2, Belgian=5, South-African=3) blood.

- A. Comparison of geometric mean of relative overlap frequencies (F metrics by VDJ tools) within pairs of fetal, cord, 10w or adult blood donors, each dot represents the F value of a pair of samples.
- B. Number of clonotypes shared within pairs of fetal, cord, 10w or adult blood donors, each dot represents a pair comparison.
- C. Number of N additions, each dot represents the weighted mean of an individual sample.
- D. J gene segment usage distribution. (Error bars indicate means \pm SEM; numbers in brackets refer to the J gene segment length).
- E. CDR3 length (nucleotide count including the C-start and F-end residues), each dot represents the weighted mean of an individual sample.
- F. Comparison of geometric mean of relative overlap frequencies (F metrics by VDJ tools) within pairs of fetal, cord, 10w and or adult blood donors, in TRDJ1 repertoire (left panel) and TRDJ3 repertoire (right panel) of sorted V γ 9V δ 2 T cells derived from fetal (n=5, Belgian), cord (n=9, Belgian=6, South-African=3), 10w (n=14, South-African) and adult (n=11 for V γ 9V δ 2, Belgian=8, South-African=3 and n=8 for nonV γ 9V δ 2, Belgian=5, South-African=3) blood. Each dot represents the F value of a pair of samples.

G-H. Description of the CDR3 TRD repertoire of sorted V γ 9V δ 2 T cells (left panels) and nonV γ 9V δ 2 $\gamma\delta$ T cells (right panels), derived from fetal (n=5, Belgian), cord (n=9, Belgian=6, South-African=3), 10w (n=14, South-African) and adult (n=11 for V γ 9V δ 2, Belgian=8, South-African=3 and n=8 for nonV γ 9V δ 2, Belgian=5, South-African=3) blood.

- G. Relative abundance of the 10w repertoire overlapping with fetal, cord or adult repertoire. Each dot represents a pair comparison.
- H. Number of clonotypes shared between the 10w repertoire and fetal, cord or adult repertoire in V γ 9V δ 2 T cells. Each dot represents a pair comparison.
- I. Representative shared clonotype abundance plots for one 10w V γ 9V δ 2 TRD repertoire versus one fetal (top), one cord (middle) and one adult (bottom) V γ 9V δ 2 TRD repertoire. The shared top 20 clonotypes between two samples are each represented in a distinct color. The frequency of these clonotypes in each sample is represented on the left side for 10w and on right side for fetal, cord, or adult. The other shared clonotypes are represented in dark grey. The rest of the repertoire (that is thus non-overlapping) is represented in light grey. Note that only up to 25% of the repertoire is shown.

Data shown from independent donors (from Belgium in round symbols, from South-Africa in square symbols, pair comparisons including both Belgian and South-African samples in triangle symbols). Bars indicate medians (a-c, e-h, j). *P*-values are reported on graphs.

Figure 3

V γ 9V δ 2 T cells are activated and become cytotoxic rapidly after birth.

- A. Percentages of activated (HLA-DR+) cells among V γ 9V δ 2 T cells (cord, adult n=8, 10w n=16).
- B. Percentages of naive (CD27+CD28+) V γ 9V δ 2 T cells (left panel) and representative flow plots (right panel).
- C-F. Percentages of $\alpha\beta$ T cells, V γ 9+V δ 2+ $\gamma\delta$ T cells, V γ 9+V δ 2- $\gamma\delta$ T cells, V γ 9-V δ 2+ $\gamma\delta$ T cells and V γ 9-V δ 2- $\gamma\delta$ T cells expressing:
 - C. NKG2A in cord (n=4), 10w (n=8-10) and adult (n=3-4).
 - D. NKG2D in cord (n=4-5), 10w (n=8-10) and adult (n=4-5).
 - E. granzyme B in cord (n=7), 10w (n=14) and adult (n=7).
 - F. perforin in cord (n=5), 10w (n=10) and adult (n=5).
- G. Representative co-expression flow cytometry plots of granzyme A, granzyme B, perforin and granulysin in cord, 10w and adult V γ 9V δ 2 T cells.
- H-I. Percentages of $\alpha\beta$ T cells, V γ 9+V δ 2+ $\gamma\delta$ T cells, V γ 9+V δ 2- $\gamma\delta$ T cells, V γ 9-V δ 2+ $\gamma\delta$ T cells and V γ 9-V δ 2- $\gamma\delta$ T cells expressing:
 - H. granulysin in cord (n=7), 10w (n=14) and adult (n=7).
 - I. granzyme A in cord (n=7), 10w (n=14) and adult (n=7).

Data shown from independent donors (South-African). Bars indicate medians (a,b). Error bars indicate medians \pm IQR (e-f, h-i). *P* values are reported on graphs.

Figure 4

The cytokine expression capacity of V γ 9V δ 2 T cells is mainly determined before birth.

A-C. Flow cytometry data on $\alpha\beta$ T cells, $V\gamma 9+V\delta 2+$ $\gamma\delta$ T cells, $V\gamma 9+V\delta 2-$ $\gamma\delta$ T cells, $V\gamma 9-V\delta 2+$ $\gamma\delta$ T cells and $V\gamma 9-V\delta 2-$ $\gamma\delta$ T cells.

- A. IFN γ expression after 4-hour PMA-Ionomycin stimulation: percentage of positive cells (left panel; cord, adult n=12, 10w=24) and median fluorescent intensity (right panel; cord, adult n=4, 10w=8).
- B. TNF α expression after 4-hour PMA-Ionomycin stimulation: percentage of positive cells (left panel; cord n=8, 10w=17, adult n=9) and representative co-expression flow plots of IFN γ and TNF α in cord, 10w and adult $V\gamma 9V\delta 2$ T cells (right panel).
- C. Ex-vivo expression of T-bet (left panel) and Eomes (right panel) (cord, adult n=7-8, 10w=14-16).
- D. Percentage of IFN γ + cells among $V\gamma 9V\delta 2$ T cells after stimulation with the phosphoantigen HMB-PP (3 days or overnight, in presence of IL-2; cord, adult n=8, 10w=16). Values derived from 'medium+IL-2' condition are subtracted.
- E. Percentage of IFN γ + cells among $V\gamma 9V\delta 2$ T cells after stimulation with zoledronic acid (3 days, in presence of IL-2; cord, adult n=6, 10w=12). Values derived from 'medium+IL-2' condition are subtracted.

Data shown from independent donors (South-African). Error bars indicate medians \pm IQR (a-c). Bars indicate medians (d-e). P values are reported on graphs.

Figure 5

Neonatal BCG vaccination does not shape of the 10-week-old $V\gamma 9V\delta 2$ TCR repertoire.

- A. Frequencies of the $V\gamma 9+V\delta 2+$ subset in 10-week-old unvaccinated infants (10w BCG-) or vaccinated infants (10w BCG+) CD3+ cells (top panel; n=18) and percentage of Ki-67+ cells among $V\gamma 9V\delta 2$ T cells (bottom panel; n=7)).
- B-H. Comparison of the CDR3 TRDV2 (top row) and TRGV9 (bottom row) repertoire of sorted $V\gamma 9V\delta 2$ T cells derived from 10w BCG- (n=7) and 10w BCG+ (n=7) blood.
 - B. Representative tree-maps showing CDR3 clonotype usage for BCG- (left) and BCG+ (right) $V\gamma 9V\delta 2$ T cells; each rectangle represents one CDR3 clonotype and its size corresponds to its relative frequency in the repertoire (rectangle colors are chosen randomly and do not match between plots).
 - C. Comparison of D25 values (percentage of unique clonotypes required to account for 25% of total repertoire).
 - D. Number of N additions, each dot represents the weighted mean of an individual sample.
 - E. J gene segment usage distribution (Error bars indicate mean \pm SEM).
 - F. CDR3 length (nucleotide count including the C-start and F-end residues), each dot represents the weighted mean of an individual sample (left panel); frequency of repertoire per CDR3 length (right panel).
 - G. Comparison of geometric mean of relative overlap frequencies (F metrics by VDJ tools) within pairs of BCG- or pairs of BCG+ infants; each dot represents the F value of a pair of samples.
 - H. Relative abundance of the BCG- or BCG+ repertoire overlapping with fetal. Each dot represents a pair comparison.

Data shown from independent donors (South-African). Bars indicate medians (a, c-d, f left panel, g-h). Error bars indicate medians \pm IQR (e, f right panel). P values are reported on graphs.

Figure 6

Neonatal BCG vaccination does not influence the functional differentiation of 10-week-old V γ 9V δ 2 T cells.

PCA analysis profiling of V γ 9V δ 2 T cells derived from cord, 10-week-old BCG-, 10-week-old BCG+ and adult blood (n=5), based on the percentage of: HLA-DR+, CD27-CD28-, CD27-CD28+, CD27+CD28-, CD27-CD28-, T-bet+, Eomes+, granzyme A+, granzyme B+, perforin+, granulysin+, IFN γ + and TNF α + cells. Data shown from independent donors (South-African).

Table 1: The most shared CDR3 δ clonotypes among 10-week-old (10w) V γ 9V δ 2 T cells.

CDR3 clonotype (aa)	Number of N additions	Occurrences (/14)	Median Abundance
CACDILGDTDKLIF	0	13	3.298%
CACDTVLGDTWDTRQMFF	0	13	0.858%
CACDTVLGDSWDTRQMFF	0	13	0.337%
CACDVLGDTDKLIF	0	12	2.598%
CACDILGDTAQLFF	0	10	0.694%
CACDTWGYTDKLIF	1/0*	10	0.572%
CACDTWGTDKLIF	0	10	0.258%
CACDTLGDTDKLIF	0	9	0.250%
CACDILGDTLTAQLFF	0	9	0.222%
CACDSTGGYSWDTRQMFF	0	9	0.146%
CACDTAGGYSWDTRQMFF	1	9	0.047%
CACDTVGDTDKLIF	1	8	0.388%
CACDNTGGYSWDTRQMFF	1	8	0.122%
CACDTWGMTAQLFF	0	8	0.116%
CACDTWGSSWDTRQMFF	0	8	0.094%
CACDVLGDLTAQLFF	0	8	0.078%
CACDTWDTRQMFF	0	8	0.024%
CACDTVLGDTDKLIF	0	8	0.003%

Clonotypes detected in more than 50% of the 10w donors are shown. CDR3 clonotype (aa): amino acid CDR3 sequence; number of N additions incorporated in the nucleotide(s) encoding each clonotype; occurrences: number of donors where the clonotype was detected (out of 14); median abundance: median percentage of repertoire in the fourteen 10w donors. *Of the two nucleotides encoding this clonotype, one is germline and one includes one N addition. (aa: amino acid).











